Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes

Neuroscience

Volumn 169, Issue 3, 2010, Pages 1063-1070

  Beurel, E ^a   Jope, R S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Astrocytes; GSK3; LPS; Neuroinflammation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENCEPHALITIS; ENZYME INHIBITION; ENZYME REGULATION; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

EID: 77955274025     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.05.044     Document Type: Article

References (39)

1. Beurel E., Jope R.S. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 2008, 283:21934-21944.
2. Beurel E., Jope R.S. Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharide-induced IL-6 production in RAW2647 cells. Cell Signal 2009, 21:978-985.
3. Beurel E., Jope R.S. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 2009, 6:9.
4. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009, 14:1095-1104.
5. Campbell I.L., Stalder A.K., Chiang C.S., Bellinger R., Heyser C.J., Steffensen S., Masliah E., Powell H.C., Gold L.H., Henriksen S.J., Siggins G.R. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry 1997, 2:125-129.
6. Cavaillon J.M., Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006, 10:233-240.
7. Cerciat M., Unkila M., Garcia-Segura L.M., Arevalo M.A. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 2010, 58:93-102.
8. Cohen P., Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001, 2:769-776.
9. Craft J.M., Watterson D.M., Van Eldik L.J. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets 2005, 9:887-900.
10. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
11. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186.
12. Dugan L.L., Ali S.S., Shekhtman G., Roberts A.J., Lucero J., Quick K.L., Behrens M.M. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS One 2009, 4:e5518.
13. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
14. Freudenberg M.A., Galanos C. Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. Int Rev Immunol 1990, 6:207-221.
15. Guo L.H., Schluesener H.J. Acute but not chronic stimulation of glial cells in rat spinal cord by systemic injection of lipopolysaccharide is associated with hyperalgesia. Acta Neuropathol 2006, 112:703-713.
16. Hirschfeld M., Ma Y., Weis J.H., Vogel S.N., Weis J.J. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000, 165:618-622.
17. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 2000, 406:86-90.
18. Jope R.S. Lithium and GSK3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003, 24:441-443.
19. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29:95-102.
20. Kariko K., Weissman D., Welsh F.A. Inhibition of toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 2004, 24:1288-1304.
21. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996, 93:8455-8459.
22. Lee M., Sparatore A., Del Soldato P., McGeer E., McGeer P.L. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 2010, 58:103-113.
23. Leost M., Schultz C., Link A., Wu Y.Z., Biernat J., Mandelkow E.M., Bibb J.A., Snyder G.L., Greengard P., Zaharevitz D.W., Gussio R., Senderowicz A.M., Sausville E.A., Kunick C., Meijer L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 2000, 267:5983-5994.
24. Marsland A.L., Gianaros P.J., Abramowitch S.M., Manuck S.B., Hariri A.R. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008, 64:484-490.
25. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784.
26. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002, 45:1292-1299.
27. McCarthy K.D., de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980, 85:890-902.
28. McManus E.J., Sakamoto K., Armit L.J., Ronaldson L., Shpiro N., Marquez R., Alessi D.R. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005, 24:1571-1583.
29. Medvedev A.E., Kopydlowski K.M., Vogel S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 2000, 164:5564-5574.
30. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
31. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439.
32. Schneider D.S., Ayres J.S. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol 2008, 8:889-895.
33. Shemi D., Kaplanski J. Involvement of PGE2 and TNF-alpha in LPS-tolerance in rat glial primary cultures. Prostaglandins Leukot Essent Fatty Acids 2005, 73:385-389.
34. Sironi M., Bianchi M., Riganti F., Ghezzi P. Suppression of interleukin-6 production in endotoxin tolerance in a mouse glioma cell line: reversal by phorbol ester. Lymphokine Cytokine Res 1993, 12:39-43.
35. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668.
36. Steinbrecher K.A., Wilson W., Cogswell P.C., Baldwin A.S. Glycogen synthase kinase 3β functions to specify gene-specific, NF-βB-dependent transcription. Mol Cell Biol 2005, 25:8444-8455.
37. Wagman A.S., Johnson K.W., Bussiere D.E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004, 10:1105-1137.
38. Yuskaitis C.J., Jope R.S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 2009, 21:264-273.
39. Ziegler-Heitbrock H.W. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 1995, 45:13-26.